Advances in Antimicrobial Treatment

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Antimicrobial Agents and Resistance".

Deadline for manuscript submissions: 15 July 2025 | Viewed by 280

Special Issue Editors


E-Mail Website
Guest Editor
Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico
Interests: viral infection; antiviral; emerging diseases; antiviral therapies; vaccines; bioinformatics; clinical trials

E-Mail Website
Guest Editor
Instituto Nacional de Perinatología, Ciudad de México 11000, Mexico
Interests: viral infection; viral replication; antivirals; vertical viral infections
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The ongoing battle against microbial pathogens, including viruses, bacteria, and fungi, continues to challenge global health systems, particularly in the face of rising antimicrobial resistance. This Special Issue of Microorganisms invites groundbreaking research and comprehensive reviews that advance our understanding and treatment of microbial infections. Contributions may explore novel therapeutic strategies, including drug development, the repurposing of existing antivirals, antibacterial and antifungal agents, innovative combination therapies, and alternative approaches such as phage therapy and immune modulation.

We particularly welcome studies employing cutting-edge methodologies, such as in silico modeling, high-throughput screening, and omics technologies, to identify potential antimicrobial targets and optimize therapeutic interventions. Submissions addressing the mechanisms of resistance, host–pathogen interactions, or the clinical translation of antimicrobial agents are also encouraged.

This Issue showcases diverse perspectives and innovative solutions, aiming to inspire collaboration and accelerate progress in combating infectious diseases, ultimately contributing to improved global health outcomes.

Dr. Luis Adrián De Jesús-González
Dr. Moises Leon-Juarez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial resistance
  • novel therapies
  • drug repurposing
  • antiviral agents
  • antibacterial agents
  • antifungal agents
  • microbial pathogens
  • host–pathogen interactions
  • omics technologies
  • phage therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1500 KiB  
Article
A Decade of Pediatric CA-MRSA Surveillance in Northern Taiwan: Retrospective Resistance Analysis and Recent Genotypic Characterization
by Chia-Ning Chang, Chia-Hsiang Yu and Chih-Chien Wang
Microorganisms 2025, 13(5), 1013; https://doi.org/10.3390/microorganisms13051013 - 28 Apr 2025
Viewed by 47
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of pediatric infections and has shown evolving molecular characteristics over time. This study aimed to investigate the phenotypic and genotypic features of MRSA isolates collected from pediatric patients at a tertiary medical center in northern [...] Read more.
Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of pediatric infections and has shown evolving molecular characteristics over time. This study aimed to investigate the phenotypic and genotypic features of MRSA isolates collected from pediatric patients at a tertiary medical center in northern Taiwan between 2011 and 2020. A total of 182 MRSA strains were analyzed for SCCmec types, PVL gene presence, antimicrobial susceptibility, multilocus sequence typing (MLST), and clonal relatedness using pulsed-field gel electrophoresis (PFGE). ST59/SCCmec Vt was the most prevalent genotype, followed by ST59/SCCmec IV and ST8/SCCmec IV. Most ST59/SCCmec Vt and ST8/SCCmec IV isolates clustered genetically. Clindamycin and erythromycin resistance remained high, whereas co-trimoxazole susceptibility ranged from 76% to 100%. These findings confirm ST59 as the dominant clone and highlight the emergence of ST8 and ST45 in community-associated MRSA (CA-MRSA) infections. Oral co-trimoxazole remains the most effective empirical option, while clindamycin and erythromycin should be avoided. Continuous molecular surveillance is warranted to monitor trends and guide treatment strategies in pediatric MRSA infections. Full article
(This article belongs to the Special Issue Advances in Antimicrobial Treatment)
Show Figures

Figure 1

Back to TopTop